National Academies Press: OpenBook

Drug Repurposing and Repositioning: Workshop Summary (2014)

Chapter: Appendix D: Registered Attendees

« Previous: Appendix C: Statement of Task
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×

D

Registered Attendees

Deborah Amey

Private citizen

Naomi Aronson

Blue Cross and Blue Shield Association

Mike Bailey

Legg Mason

Ronald Bartek

Friedreich Ataxia Research Alliance

Andrea Bennett

American Society for Clinical Pathology

Paul Billings

Life Technologies

Bruce Bloom

Cures Within Reach

Bruce Blumberg

Kaiser Permanente

Sue Bogner

Institute for the Study of Human Error LLC

Mary Bordoni

Personalized Medicine Coalition

Khaled Bouri

U.S. Food and Drug Administration

Jane Boylan

Providence Health Systems

Pamela Bradley

U.S. Food and Drug Administration

Linda Brady

National Institute of Mental Health

Joel Brill

Predictive Health LLC

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×

Phillip J. Brooks

Office of Rare Diseases Research

National Institutes of Health

Jonca Bull

U.S. Food and Drug Administration

Atul Butte

Stanford University

Lon Cardon

GlaxoSmithKline

Michael Carleton

American University

Alex Carney

Melanoma Research Alliance

Ann Cashion

National Institute of Nursing Research

National Institutes of Health

C. Thomas Caskey

Baylor College of Medicine

Pascaline Clerc

Humane Society of the United States

Christine Colvis

National Center for Advancing Translational Sciences

National Insitutes of Health

Tom Daniel

Celgene

Sean David

Stanford University

Ulyana Desiderio

American Society of Hematology

Harry Dietz

Johns Hopkins University School of Medicine

Sarah Dorff

U.S. Food and Drug Administration

Michael Dougherty

American Society of Human Genetics

Michele Doughty

A.T. Still University

Lee Dudka

Dudka & Associates

Keith Egan

American Association of Colleges of Osteopathic Medicine

William Feero

Journal of the American Medical Association

Christine Foster

Teva Pharmaceuticals

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×

Don Frail

AstraZeneca

Gopi Ganji

GlaxoSmithKline

Vikrham Kumar Gerraa

FasterCures

Geoffrey Ginsburg

Duke University

Aliza Glasner

O’Neill Institute for National and Global Health Law

Georgetown University Law Center

Christian Grimstein

U.S. Food and Drug Administration

Cindy Hahn

Alagille Syndrome Alliance

Jennifer Hall

University of Minnesota

Kim Harp

J. Terrell Hoffeld

U.S. Public Health Service

Marsha Holloman

Office of Medical Policy

Center for Drug Evaluation and Research

U.S. Food and Drug Administration

Mark Hurle

GlaxoSmithKline

Edward Ivy

Maternal and Child Health Bureau

Health Resources and Services Administration

Brett Johnson

Stoneface Ventures

Samuel Johnson

Kaiser Permanente

Colorado

Rasika Kalamegham

American Association of Cancer Research

Petra Kaufmann

Office of Clinical Research

National Institute of Neurological Disorders and Stroke

Chris Khoury

Health Research Institute

PricewaterhouseCoopers

Muin Khoury

Office of Public Health Genomics

Centers for Disease Control and Prevention

Katherine Lambertson

Genetic Alliance

Jeffrey Lang

IMS Health

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×

Gabriela Lavezzari

Pharmaceutical Research and Manufacturers of America

Thomas Lehner

National Institute of Mental Health

Debra G. B. Leonard

University of Vermont College of Medicine

Peter Levin

FirstLine

Jack Lewin

National Coalition on Health Care

Jonathan Liang

Genetic Alliance

Monica Liebert

Association for Clinical and Translational Science

Mark David Lim

FasterCures

Debra Lyon

Virginia Commonwealth University

Cheryl Marks

National Cancer Institute

Michael McCaughan

Regulation Policy Market Access Report

Robert McCormack

Veridex, LLC

John McKew

National Institutes of Health

Kelly Marie McVearry

Northrop Grumman Health IT

Amy Miller

Personalized Medicine Coalition

Takashi Mochizuki

Daiichi Sankyo Company, Ltd.

Rebecca Nagy

National Society of Genetic Counselors

Neal Neuberger

Health Tech Strategies

Paul Nisson

Bentley Management

Michael Pacanowski

Office of Clinical Pharmacology

U.S. Food and Drug Administration

Dominique Pahud

Kauffman Foundation

Devang Parikh

Pfizer Inc.

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×

Syril Pettit

U.S. Health and Environmental Sciences Institute

Sreekumar Pillai

Eli Lilly and Company

Aidan Power

Pfizer Inc.

Ronald Przygodzki

U.S. Department of Veterans Affairs

Resha Putzrth

Navy Marine Corps Public Health Center

U.S. Navy

Nalini Raghavachari

National Institute on Aging

National Institutes of Health

Arti Rai

Duke University Law School

Mary Relling

St. Jude Children’s Research Hospital

John Reppas

Neurotechnology Industry Organization

Michael Ringel

The Boston Consulting Group

Bob Roehr

Freelance journalist

Allen Roses

Duke University

Deborah Runkle

American Association for the Advancement of Science

Raymond Francis Sarmiento

National Library of Medicine

Sheri Schully

National Cancer Institute

Joan Scott

National Coalition for Health

Professional Education in Genetics

Regina Searcy

Searcy Venture Group

Jordi Serratosa

European Food Safety Authority

Cecili Sessions

Air Force Medical Support Agency

Sal Shah

Shah Associates MD LLC

Shalin Shah

Shah Associates MD LLC

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×

Paul Sheives

Biotechnology Industry Organization

Samuel Shekar

Northrop Grumman Information Systems

Ira Shoulson

Georgetown University

Larry Sklar

University of New Mexico Center for Molecular Discovery

Orla Smith

Science

Katie Johansen Taber

American Medical Association

Simeon Taylor

Bristol-Myers Squibb

Retta Terry

U.S. Department of Health and Human Services

Sharon Terry

Genetic Alliance

Rosemary Tiernan

Office of Medical Policy

U.S. Food and Drug Administration

Weida Tong

National Center for Toxological Research

U.S. Food and Drug Administration

David Veenstra

University of Washington

Chris Watkins

Medical Research Council

Michael Watson

American College of Medical Genetics

Jennifer Weisman

Strategic Analysis, Inc.

Matt Wenham

Institute on Science for Global Policy

Catherine Wicklund

Northwestern University

Erin Wilhelm

Georgetown University

Janet Williams

University of Iowa

Shimere Williams

Lewis-Burke Associates

Susan Wolf

University of Minnesota

Huichun Xu

National Institutes of Health

Lun Yang

GlaxoSmithKline

Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×
Page 91
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×
Page 92
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×
Page 93
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×
Page 94
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×
Page 95
Suggested Citation:"Appendix D: Registered Attendees." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×
Page 96
Drug Repurposing and Repositioning: Workshop Summary Get This Book
×
 Drug Repurposing and Repositioning: Workshop Summary
Buy Paperback | $38.00 Buy Ebook | $30.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Drug development can be time-consuming and expensive. Recent estimates suggest that, on average, it takes 10 years and at least $1 billion to bring a drug to market. Given the time and expense of developing drugs de novo, pharmaceutical companies have become increasingly interested in finding new uses for existing drugs - a process referred to as drug repurposing or repositioning.

Historically, drug repurposing has been largely an unintentional, serendipitous process that took place when a drug was found to have an offtarget effect or a previously unrecognized on-target effect that could be used for identifying a new indication. Perhaps the most recognizable example of such a successful repositioning effort is sildenafil. Originally developed as an anti-hypertensive, sildenafil, marketed as Viagra and under other trade names, has been repurposed for the treatment of erectile dysfunction and pulmonary arterial hypertension. Viagra generated more than $2 billion worldwide in 2012 and has recently been studied for the treatment of heart failure.

Given the widespread interest in drug repurposing, the Roundtable on Translating Genomic-Based Research for Health of the Institute of Medicine hosted a workshop on June 24, 2013, in Washington, DC, to assess the current landscape of drug repurposing activities in industry, academia, and government. Stakeholders, including government officials, pharmaceutical company representatives, academic researchers, regulators, funders, and patients, were invited to present their perspectives and to participate in workshop discussions. Drug Repurposing and Repositioning is the summary of that workshop. This report examines enabling tools and technology for drug repurposing; evaluates the business models and economic incentives for pursuing a repurposing approach; and discusses how genomic and genetic research could be positioned to better enable a drug repurposing paradigm.

READ FREE ONLINE

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!